Rethink field services: Three myths keeping access barriers in front of your product
Feature Article: 20 Years After the National Health Insurance Act, HTA Policy Changes Reshape Market Access in South Korea
Market Trends and Updates: New Pharmaceutical Policies Have Dramatically Changed the Landscape in China
Therapeutic Spotlight: New Evidence Brings Cautious Optimism to Alzheimer’s Disease Treatment
Webinar | Navigating COVID-19: Simplifying the Path to Better Patient Outcomes
Pharma in the field: Sales reps vs. reimbursement and access specialists
The Future of Payer Engagement: How Pharma Can Break Through
The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving
Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance
Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball
Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies
Biosimilars: Launch Insights From the Field
How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.
Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
Rise of Complex Technologies and a Challenging Reimbursement Landscape: How a Forward-Looking Indirect Treatment Comparison Feasibility Study Can Help Navigate Market Access
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
What Do Payers Think About Digital Health Technologies
How are payers thinking about apps, wearables and other digital health technologies?
Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options
Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine
HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients
Payer Perceptions and Utilization of ICER Value Assessment Framework
Xcenda examines the impact of the ICER value assessment framework on payer perceptions.